{"id":"https://openalex.org/W4288009948","doi":"https://doi.org/10.1056/evidoa2100055","title":"Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis","display_name":"Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis","publication_year":2022,"publication_date":"2022-07-26","ids":{"openalex":"https://openalex.org/W4288009948","doi":"https://doi.org/10.1056/evidoa2100055","pmid":"https://pubmed.ncbi.nlm.nih.gov/38319878"},"language":"en","primary_location":{"id":"doi:10.1056/evidoa2100055","doi":"https://doi.org/10.1056/evidoa2100055","is_oa":false,"landing_page_url":"https://doi.org/10.1056/evidoa2100055","pdf_url":null,"source":{"id":"https://openalex.org/S4210196357","display_name":"NEJM Evidence","issn_l":"2766-5526","issn":["2766-5526"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NEJM Evidence","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054286469","display_name":"Jack D. Sobel","orcid":"https://orcid.org/0000-0002-5589-4609","observed_orcids":["https://orcid.org/0000-0002-5589-4609"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jack D. Sobel","raw_affiliation_strings":["Department of Internal Medicine, School of Medicine, Wayne State University, Detroit"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, School of Medicine, Wayne State University, Detroit","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003323285","display_name":"Gilbert G.G. Donders","orcid":"https://orcid.org/0000-0001-9890-6254","observed_orcids":["https://orcid.org/0000-0001-9890-6254"]},"institutions":[{"id":"https://openalex.org/I4210102047","display_name":"Antwerp University Hospital","ror":"https://ror.org/01hwamj44","country_code":"BE","type":"funder","lineage":["https://openalex.org/I4210102047"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Gilbert Donders","raw_affiliation_strings":["Department of Obstetrics and Gynecology, Regional Hospital H Hart Tienen, Femicare Research Tienen, University Hospital Antwerp, Tienen, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology, Regional Hospital H Hart Tienen, Femicare Research Tienen, University Hospital Antwerp, Tienen, Belgium","institution_ids":["https://openalex.org/I4210102047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068329483","display_name":"Thorsten P. Degenhardt","orcid":"https://orcid.org/0000-0002-9424-0931","observed_orcids":["https://orcid.org/0000-0002-9424-0931"]},"institutions":[{"id":"https://openalex.org/I4210161705","display_name":"Mycovia Pharmaceuticals (United States)","ror":"https://ror.org/04j9kzt69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210161705"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thorsten Degenhardt","raw_affiliation_strings":["Mycovia Pharmaceuticals, Inc., Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mycovia Pharmaceuticals, Inc., Durham, NC","institution_ids":["https://openalex.org/I4210161705"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110928339","display_name":"Karen Person","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210161705","display_name":"Mycovia Pharmaceuticals (United States)","ror":"https://ror.org/04j9kzt69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210161705"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Person","raw_affiliation_strings":["Mycovia Pharmaceuticals, Inc., Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mycovia Pharmaceuticals, Inc., Durham, NC","institution_ids":["https://openalex.org/I4210161705"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009392644","display_name":"Stacey Curelop","orcid":"https://orcid.org/0000-0002-3622-6357","observed_orcids":["https://orcid.org/0000-0002-3622-6357"]},"institutions":[{"id":"https://openalex.org/I4210161705","display_name":"Mycovia Pharmaceuticals (United States)","ror":"https://ror.org/04j9kzt69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210161705"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey Curelop","raw_affiliation_strings":["Mycovia Pharmaceuticals, Inc., Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mycovia Pharmaceuticals, Inc., Durham, NC","institution_ids":["https://openalex.org/I4210161705"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089635085","display_name":"Mahmoud Afif Ghannoum","orcid":"https://orcid.org/0000-0002-8833-7323","observed_orcids":["https://orcid.org/0000-0002-8833-7323"]},"institutions":[{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mahmoud Ghannoum","raw_affiliation_strings":["Department of Pathology, Case Western Reserve University School of Medicine, Cleveland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Case Western Reserve University School of Medicine, Cleveland","institution_ids":["https://openalex.org/I58956616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041510712","display_name":"Stephen R. Brand","orcid":"https://orcid.org/0000-0002-1796-5584","observed_orcids":["https://orcid.org/0000-0002-1796-5584"]},"institutions":[{"id":"https://openalex.org/I4210161705","display_name":"Mycovia Pharmaceuticals (United States)","ror":"https://ror.org/04j9kzt69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210161705"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen R. Brand","raw_affiliation_strings":["Mycovia Pharmaceuticals, Inc., Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mycovia Pharmaceuticals, Inc., Durham, NC","institution_ids":["https://openalex.org/I4210161705"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.3327,"has_fulltext":false,"cited_by_count":61,"citation_normalized_percentile":{"value":0.97190142,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"1","issue":"8","first_page":"EVIDoa2100055","last_page":"EVIDoa2100055"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10428","display_name":"Reproductive tract infections research","score":0.008500000461935997,"subfield":{"id":"https://openalex.org/subfields/2404","display_name":"Microbiology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oteseconazole","display_name":"oteseconazole","score":0.9940000176429749},{"id":"https://openalex.org/keywords/recurrent-vulvovaginal-candidiasis","display_name":"recurrent vulvovaginal candidiasis","score":1.0},{"id":"https://openalex.org/keywords/cyp51-inhibitors","display_name":"CYP51 inhibitors","score":0.8080000281333923},{"id":"https://openalex.org/keywords/antifungal-therapy","display_name":"antifungal therapy","score":0.7179999947547913},{"id":"https://openalex.org/keywords/time-to-recurrence","display_name":"time to recurrence","score":0.7900000214576721},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.44200000166893005},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.7910000085830688},{"id":"https://openalex.org/keywords/women-s-health","display_name":"women's health","score":0.49300000071525574},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.40799999237060547},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.36500000953674316},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.46000000834465027}],"concepts":[{"id":"https://openalex.org/C2910082039","wikidata":"https://www.wikidata.org/wiki/Q977090","display_name":"Vulvovaginal Candidiasis","level":3,"score":0.9007404446601868},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7742379903793335},{"id":"https://openalex.org/C2780651595","wikidata":"https://www.wikidata.org/wiki/Q411478","display_name":"Fluconazole","level":3,"score":0.7588205337524414},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6329367160797119},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6067542433738708},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5721420049667358},{"id":"https://openalex.org/C2780670043","wikidata":"https://www.wikidata.org/wiki/Q139137","display_name":"Candida glabrata","level":3,"score":0.5580757856369019},{"id":"https://openalex.org/C2780917455","wikidata":"https://www.wikidata.org/wiki/Q310443","display_name":"Candida albicans","level":2,"score":0.5373996496200562},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4703303277492523},{"id":"https://openalex.org/C145081991","wikidata":"https://www.wikidata.org/wiki/Q2576388","display_name":"Corpus albicans","level":3,"score":0.422995924949646},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.3457120656967163},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.07467907667160034},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.058164358139038086},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0580691397190094},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002181","descriptor_name":"Candidiasis, Vulvovaginal","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1056/evidoa2100055","doi":"https://doi.org/10.1056/evidoa2100055","is_oa":false,"landing_page_url":"https://doi.org/10.1056/evidoa2100055","pdf_url":null,"source":{"id":"https://openalex.org/S4210196357","display_name":"NEJM Evidence","issn_l":"2766-5526","issn":["2766-5526"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NEJM Evidence","raw_type":"journal-article"},{"id":"pmid:38319878","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38319878","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NEJM evidence","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":25,"referenced_works":["https://openalex.org/W1490778919","https://openalex.org/W1984612322","https://openalex.org/W2006658793","https://openalex.org/W2012087078","https://openalex.org/W2069740607","https://openalex.org/W2099216984","https://openalex.org/W2106311471","https://openalex.org/W2157607248","https://openalex.org/W2170781826","https://openalex.org/W2174399815","https://openalex.org/W2185069069","https://openalex.org/W2216117396","https://openalex.org/W2329116938","https://openalex.org/W2565813012","https://openalex.org/W2746230075","https://openalex.org/W2790841582","https://openalex.org/W2791596010","https://openalex.org/W2809133082","https://openalex.org/W2882984619","https://openalex.org/W2884354402","https://openalex.org/W2891999566","https://openalex.org/W2994988388","https://openalex.org/W3007795453","https://openalex.org/W3044097033","https://openalex.org/W3080884461"],"related_works":["https://openalex.org/W4319447653","https://openalex.org/W4200522349","https://openalex.org/W4416026172","https://openalex.org/W4386305624","https://openalex.org/W4210341287","https://openalex.org/W4285806951","https://openalex.org/W4387826751","https://openalex.org/W3214098114","https://openalex.org/W4384339436","https://openalex.org/W7212374308"],"abstract_inverted_index":{"BACKGROUND:":[0],"Management":[1],"of":[2,26,115,162,263],"recurrent":[3],"vulvovaginal":[4,81],"candidiasis":[5,82],"(RVVC)":[6],"is":[7,20],"an":[8,217],"unmet":[9],"clinical":[10],"challenge":[11],"without":[12,33],"approved":[13],"treatment":[14],"in":[15,153,157,179,186,188,202,211,272,296,307],"the":[16,86,91,96,140,159,189,203,221,308],"United":[17],"States.":[18],"Oteseconazole":[19],"a":[21],"novel":[22],"oral":[23,116],"selective":[24],"inhibitor":[25],"fungal":[27],"CYP51,":[28],"designed":[29],"to":[30,54,66,112,129,177,184,195,200,224,248,255],"treat":[31],"RVVC":[32,168,218,303],"off-target":[34],"toxicities.":[35],"VIOLET":[36],"comprised":[37],"two":[38],"global,":[39],"phase":[40],"3,":[41],"multicenter,":[42],"randomized,":[43],"double-blind,":[44],"placebo-controlled":[45],"trials":[46],"(CL-011":[47],"and":[48,70,121,155,181,197,213,228,233,252,261,301,310,327],"CL-012).":[49],"The":[50],"primary":[51],"objective":[52],"was":[53,145,173,226,294],"evaluate":[55],"oteseconazole":[56,117,190,293],"efficacy":[57],"through":[58,170,304],"week":[59,171,305],"48.":[60],"Key":[61],"secondary":[62],"objectives":[63],"evaluated":[64],"time":[65,223],"first":[67],"recurrence,":[68],"safety,":[69],"patient-reported":[71],"outcomes.":[72],"METHODS:":[73],"Women":[74],"with":[75,100,164,275,313],"three":[76],"or":[77,128,166,280,288],"more":[78,167],"symptomatic":[79],"acute":[80,298],"(VVC)":[83],"episodes":[84,169],"within":[85],"previous":[87],"12-month":[88],"period,":[89],"including":[90],"screening":[92],"episode":[93,98,219],"(in":[94],"which":[95],"VVC":[97,299],"cleared":[99],"fluconazole":[101],"induction":[102],"therapy),":[103],"were":[104,137,268],"randomly":[105],"assigned":[106],"2:1":[107],"at":[108],"baseline":[109],"(maintenance":[110],"phase)":[111],"150":[113],"mg":[114],"daily":[118],"for":[119,125,132,236,250,257,325,329],"7days":[120],"then":[122],"once":[123],"weekly":[124],"11":[126],"weeks":[127,230,235],"matching":[130],"placebo":[131,205],"12":[133],"weeks.":[134,147],"Time-to-first-recurrence":[135],"data":[136],"collected":[138],"during":[139],"maintenance":[141],"phase.":[142],"Posttreatment":[143],"follow-up":[144],"36":[146],"RESULTS:":[148],"Among":[149,208],"656":[150],"women":[151],"(326":[152],"CL-011":[154,180,212,251,309,326],"330":[156],"CL-012),":[158],"averaged":[160],"percentage":[161],"participants":[163,210,238],"one":[165],"48":[172,306],"6.7%":[174],"(range,":[175],"6.5":[176],"7.4%)":[178],"3.9%":[182],"(3.7":[183],"4.6%)":[185],"CL-012":[187,214,311],"groups":[191,206,271],"versus":[192,231],"42.8%":[193],"(41.3":[194],"45.0%)":[196],"39.4%":[198],"(38.0":[199],"42.6%)":[201],"corresponding":[204],"(P<0.001).":[207],"oteseconazole-treated":[209],"who":[215],"experienced":[216],"(n=22),":[220],"mean":[222],"recurrence":[225,300],"45.7":[227],"47.2":[229],"27.8":[232],"33.1":[234],"placebo-treated":[237],"(n=84),":[239],"respectively":[240],"(hazard":[241],"ratio":[242],"[95%":[243],"confidence":[244],"interval],":[245],"0.11":[246],"[0.06":[247],"0.21]":[249],"0.08":[253],"[0.04":[254],"0.17]":[256],"CL-012;":[258],"P<0.001).":[259],"Types":[260],"frequencies":[262],"treatment-emergent":[264],"adverse":[265,281],"events":[266],"(TEAEs)":[267],"similar":[269],"between":[270],"both":[273],"trials,":[274,312],"no":[276],"drug-related":[277],"serious":[278],"TEAEs":[279],"effects":[282],"on":[283],"pregnancy":[284],"outcomes,":[285],"liver":[286],"function,":[287],"QT":[289],"interval.":[290],"CONCLUSIONS:":[291],"Oral":[292],"effective":[295],"preventing":[297],"treating":[302],"mostly":[314],"mild":[315],"TEAEs.":[316],"(Funded":[317],"by":[318],"Mycovia":[319],"Pharmaceuticals,":[320],"Inc.,":[321],"ClinicalTrials.gov":[322],"numbers,":[323],"NCT03562156":[324],"NCT03561701":[328],"CL-012.)":[330]},"counts_by_year":[{"year":2026,"cited_by_count":19},{"year":2025,"cited_by_count":18},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-07-26T00:00:00"}